In September 2025, the U.S. Office of Prescription Drug Promotion (OPDP) initiated a significant enforcement campaign targeting direct-to-consumer (DTC) advertising, following a White House directive on 9 September 2025, emphasizing "transparency and accuracy" in consumer facing promotional communications. That same day, the U.S. Food and Drug Administration (FDA) announced "sweeping reforms to rein in" DTC practices, including plans to initiate rulemaking to close the "adequate provision loophole" and reform the "major statement" policy requirements for risk disclosures; it also issued letters instructing Biologics License Application (BLA) and New Drug Application (NDA) holders to reassess their promotional materials.

OPDP followed with an unprecedented volume of enforcement by more modern standards, with more than 100 warning and untitled letters issued to drug manufacturers in September 2025 alone. Approximately 80% of the more than 50 untitled letters focused on DTC television advertising. Three themes dominated OPDP's concerns in the DTC untitled letters:

1. Misleading or distracting imagery: OPDP raised concerns where "attention-grabbing" visual components – including animations, rapid scene transitions, or emotionally evocative imagery – were viewed as potentially distracting from required risk information. The letters reflect FDA's continued emphasis on the overall impact of creative execution on consumer understanding.

2. Inadequate or minimized risk information: OPDP evaluated not only whether risk disclosures were included but also their clarity and prominence. Issues included compressed supers, upbeat or incongruent tones or music during the major statement, and depictions of patients engaged in activities inconsistent with the seriousness of the product's risk profile.

3. Overstatements of efficacy and unsupported claims: OPDP cited instances where benefit presentations appeared broader than the underlying evidence, or where claims drew from single arm studies, exploratory analyses, or non validated quality of life measures. These observations underscore FDA's ongoing attention to how clinical data are characterized in consumer directed materials, particularly where messaging implies transformative benefits, emotional or social restoration, or quality of life improvements.

The uptick in enforcement has continued into 2026, and we anticipate the trend will continue.

Looking forward, FDA has indicated it intends to address perceived "digital loopholes" by expanding oversight across social media and emerging promotional channels. Areas of focus will likely include influencer and sponsored content, algorithm driven targeted advertising, dark ads, AI generated health content, chatbot interactions, platform specific strategies designed to avoid detection, and new digital formats not covered by existing guidance.